GlassScriptPhysician profile
Mark Sonnenschine
NPI 1922291939
$13,494.96
in general payments reported to CMS, 2019-2025
54 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $2,002 · 2021: $2,119 · 2022: $1,699 · 2023: $2,232 · 2024: $1,999 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,135 · Education: $559 · Long Term Medical Supply Or Device Loan: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.53 |
| Education | $558.86 |
| Long Term Medical Supply Or Device Loan | $333.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,318.65 | 2019-2025 | |
| Pfizer INC. | $1,301.51 | 2019-2025 | |
| Janssen Biotech, INC. | $1,010.17 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $904.03 | 2019-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $806.01 | 2019-2024 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $755.94 | 2019-2025 | Keytruda, Lynparza, Lenvima |
| Daiichi Sankyo INC. | $622.58 | 2019-2025 | Enhertu, Injectafer |
| Celgene Corporation | $444.53 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Eisai INC. | $345.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $315.16 | 2019-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $304.08 | 2019-2025 | Ninlaro, Vpriv, Iclusig |
| Exelixis INC. | $281.95 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $254.50 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $250.50 | 2019-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $249.95 | 2022-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sonnenschine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.